FDA Recall Digest: 9 Class II Actions, No Class I — Sterility and Dissolution Failures Dominate

Ten recalls posted today, with no Class I actions requiring immediate top-line escalation. The batch is dominated by sterility assurance failures in topical and ophthalmic drug products, alongside a cluster of dissolution-specification failures in oral solid dosage forms. One item — an Amazon-distributed acetaminophen lot — remains unclassified pending FDA review.

Pending classification on a nationwide consumer OTC product warrants monitoring; discoloration complaints can signal stability or manufacturing-process deviations.

Companion recall to the 10% wash above, same contract manufacturer and same limited distribution footprint — suggests a facility-level contamination event at SV Labs Toronto.

Ophthalmic sterility failures carry heightened clinical risk given direct ocular exposure; both products should be pulled from shelf stock pending confirmation of corrective action.

Dissolution and physical-integrity failures across ER tablets and injectables underscore ongoing QC pressure in generic solid-dose and parenteral manufacturing lines.

A single-lot cold-chain excursion affecting an oncology implant; providers holding Lot YN0099 should verify chain-of-custody documentation before administration.